source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- HHS to allocate up to $4.9 million for ibogaine research targeting PTSDThe U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…